Apollo Hospitals Q2 Revenue Rises 13% to Rs 6,304 Crore

Apollo Hospitals Enterprise Ltd. (AHEL) has demonstrated strong financial performance in the second quarter of FY26 with a 13% year-on-year (YoY) revenue increase to Rs 6,304 crore along with a 26% surge in consolidated profit after tax (PAT) to Rs 477 crore.

The consolidated EBITDA for the quarter was up 15% YoY to Rs 941 crore, reflecting a sustained strong performance of healthcare services, retail healthcare & diagnostics, and digital & pharma distribution business units.

In the first half (H1) of FY26, Apollo recorded consolidated revenue of Rs 12,146 crore, which is 14% higher year-on-year. The EBITDA has grown by 20% to Rs 1,793 crore, and the PAT has increased by 33% to Rs 910 crore.

Also Read: Marksans Pharma Gets UK MHRA Nod for Exemestane Tablets

Besides, the quarter has seen the soft launch of Apollo Athenaa, Asia’s first dedicated cancer centre for women in Delhi, and Royal Mudhol Apollo Hospitals, a multi-specialty tertiary care facility in Pune. In its 42-year journey, Apollo Hospitals has performed over 5.1 million surgeries and 27,000 organ transplants, enabling more than 200 million lives in 185 countries.

Dr. Prathap C. Reddy, Chairman of Apollo Hospitals, mentioned that the group’s growth is being led by its integrated healthcare model and their going-in-the-front-door approach technology-wise. Some of the key points he made were Apollo’s pioneering clinical innovation, AI integration, and expansion that focuses on environmental aspects.

The Competition Commission of India (CCI) has also given green light to Apollo’s restructuring scheme jointly involving Apollo Healthco, Keimed, and Apollo Healthtech, thus facilitating the creation of more shareholder value and operational synergy.